Osaic Holdings
OCUL icon

Osaic Holdings’s Ocular Therapeutix OCUL Stock Holding History

Osaic Holdings’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$508K Buy
51,740
+245
+0.5% +$2.22K ﹤0.01% 3658
2026
Q1 		$436K Sell
51,495
-33,047
-39% -$315K ﹤0.01% 3482
2025
Q4 		$1.03M Buy
84,542
+58,952
+230% +$716K ﹤0.01% 2671
2025
Q3 		$316K Sell
25,590
-41,940
-62% -$502K ﹤0.01% 3816
2025
Q2 		$627K Buy
67,530
+67,180
+19,194% +$526K ﹤0.01% 2927
2025
Q1 		$2.56K Sell
350
-67,596
-99% -$520K ﹤0.01% 6495
2024
Q4 		$580K Buy
67,946
+253
+0.4% +$2.47K ﹤0.01% 2655
2024
Q3 		$589K Buy
67,693
+42
+0.1% +$346 ﹤0.01% 2710
2024
Q2 		$463K Buy
67,651
+66,526
+5,913% +$411K ﹤0.01% 2837
2024
Q1 		$10.2K Hold
1,125
– – ﹤0.01% 5729
2023
Q4 		$5.02K Sell
1,125
-350
-24% -$1.03K ﹤0.01% 6174
2023
Q3 		$4.63K Sell
1,475
-2,537
-63% -$10.4K ﹤0.01% 6307
2023
Q2 		$20.7K Sell
4,012
-945
-19% -$5.62K ﹤0.01% 5538
2023
Q1 		$26.1K Buy
4,957
+232
+5% +$1.1K ﹤0.01% 5405
2022
Q4 		$14K Sell
4,725
-100
-2% -$331 ﹤0.01% 5770
2022
Q3 		$20K Buy
4,825
+1,100
+30% +$5.54K ﹤0.01% 5585
2022
Q2 		$15K Hold
3,725
– – ﹤0.01% 5815
2022
Q1 		$18K Sell
3,725
-11,351
-75% -$62.9K ﹤0.01% 5770
2021
Q4 		$105K Buy
15,076
+10,500
+229% +$81.5K ﹤0.01% 4560
2021
Q3 		$46K Buy
4,576
+1,200
+36% +$13.5K ﹤0.01% 5179
2021
Q2 		$48K Buy
3,376
+875
+35% +$13.3K ﹤0.01% 5068
2021
Q1 		$41K Buy
2,501
+1,900
+316% +$36.6K ﹤0.01% 5006
2020
Q4 		$12K Sell
601
-549
-48% -$8.15K ﹤0.01% 5437
2020
Q3 		$9K Buy
1,150
+250
+28% +$2.08K ﹤0.01% 5334
2020
Q2 		$7K Buy
+900
New +$5.96K ﹤0.01% 5331

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Osaic Holdings's OCUL Position: Q2 2026 in Review

Osaic Holdings increased its Ocular Therapeutix (OCUL) stake by 0.48% in Q2 2026, buying an estimated $2.22K and bringing the position to 51,740 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

Osaic Holdings first reported a position in OCUL in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.03M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Osaic Holdings held 51,740 shares of Ocular Therapeutix worth $508K as of Q2 2026.
  • Osaic Holdings bought 245 Ocular Therapeutix shares in Q2 2026, an estimated $2.22K.
  • Ocular Therapeutix made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #3658 holding.
  • Osaic Holdings first reported a position in Ocular Therapeutix in Q2 2020 and has held it in 25 quarters since.
  • Osaic Holdings's Ocular Therapeutix position peaked at $1.03M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.